Richard M. Weinshilboum

Trans-ancestry genome-wide association meta-analysis of antidepressant response to selective serotonin reuptake inhibitors in clinical studies of depression

This study performs a trans-ancestry GWAS of SSRI response in depression, finding suggestive associations and enrichment in serotonergic pathways but no genome-wide significant variants.

Alcohol Use Disorder Associated Gene FNDC4 Alters Glutamatergic and GABAergic Neurogenesis

The paper identifies FNDC4 as a gene associated with alcohol use disorder through GWAS and shows its role in regulating neurogenesis via alternative splicing and CRISPR/Cas9 experiments.

OmicsFootPrint: a framework to integrate and interpret multi-omics data using circular images and deep neural networks

OmicsFootPrint integrates and interprets multi-omics data using circular images and deep neural networks, achieving high AUC scores in cancer subtype classification and drug response prediction.

Meta-analysis of CYP2C19 and CYP2D6 metabolic activity on antidepressant response from 13 clinical studies using genotype imputation

This study examines the association between CYP2C19 and CYP2D6 metabolic phenotypes and antidepressant response using genotype imputation across 13 studies, finding no significant associations after correction for multiple testing.

Glucocorticoids Unmask Silent Non-Coding Genetic Risk Variants for Common Diseases

The paper shows glucocorticoid exposure reveals the function of non-coding genetic variants linked to disease risk by influencing gene expression in relevant biological processes.

Glucocorticoids Mediate Transcriptome-wide Alternative Polyadenylation: Mechanisms and Functional Implications

This study shows glucocorticoids regulate alternative polyadenylation in human B-lymphoblastoid cells, affecting gene function and immune-related pathways.

Genetic Contributions to Alcohol Use Disorder Treatment Outcomes: A Genome-wide Pharmacogenomics Study

This study identifies genetic variants associated with AUD treatment outcomes using pharmacogenomic analyses of naltrexone and acamprosate responses.

Alterations in Acylcarnitines, Amines, and Lipids Inform about Mechanism of Action of Citalopram/Escitalopram in Major Depression

The paper uses targeted metabolomics to analyze changes in acylcarnitines, amines, and lipids in response to citalopram/escitalopram treatment in MDD patients, identifying metabolic correlates of treatment response.

Pilot Study of Metabolomic Clusters as State Markers of Major Depression and Outcomes to CBT Treatment

This study identifies metabolomic clusters associated with depressive symptom change and treatment response to CBT in MDD patients.

PANOPLY: Omics-guided drug prioritization method tailored to an individual patient

PANOPLY prioritizes cancer drugs for individual patients using multi-omics data and machine learning, showing effectiveness in a chemotherapy-resistant tumor model.

Polygenic risk scores for major depressive disorder and neuroticism as predictors of antidepressant response: meta-analysis of three treatment cohorts.

This study evaluates polygenic risk scores for MDD and neuroticism as predictors of antidepressant response across three cohorts, finding no significant prediction but consistent directional effects.

Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: meta-analysis of data from genome-wide association studies

This paper conducts a meta-analysis showing that CYP2C19 poor metabolizers have better antidepressant efficacy but similar side effects compared to extensive metabolizers.

New insights on the pharmacogenomics of antidepressant response from the GENDEP and STAR*D studies: rare variant analysis and high-density imputation

This study identifies two SNPs associated with antidepressant response in GENDEP and STAR*D studies but finds limited replication in independent cohorts.